Nesfatin-1 role in remodeling of the left ventricle myocardium in patients with arterial hypertension and obesity.
Introduction: Obesity-associated arterial hypertension (AH) is characterized by common pathogenetic mechanisms. In this data, the following facet of the obesity/hypertension nexus will be discussed: the potential mechanisms by which nesfatin-1 can lead to the left ventricle (LV) myocardium remodeling. The aim: - to estimate a nesfatin-1 role in the remodeling of the LV myocardium in patients with AH in combination with obesity and to establish existence and a charatker of communications with cardiohaemodynamics indexes. Materials and methods: In 2016-2018 a single screening study in representative sample of 105 individuals aged 59,7±3,27 - 66,43±1,26 years was performed. AH was detected with history stratified by ESH17 criteria. Body mass index (BMI) was calculated for all individuals. Obesity was diagnosed in BMI>30 kg/m2. The level of nesfatin-1 has been determined to participants of a research with the use of test system of Human NES ELISA KIT (China). Echocardiography was performed for all patients. Results: In patients with AH with normal body weight the level of nesfatin-1 was 8,07±0,06 ng/ml that is probable higher, than in persons from control group where the value of this indicator was 4,61±0,07 ng/ml (р<0,001), but lower, than in patients without obesity. Also we have obtained data about existence of direct correlation connections between the level of the nesfatin-1 and end-diastolic volume (r=0,35, р<0,05), end-systolic volume (r=0,46, р<0,05), end-diastolic size (r=0,54, р<0,05), end-systolic size (r=0,35, р<0,05) and feedback with ejection fraction of LV (r=-0,37, р<0,05) in the examined patients. Conclusions: The increased content in blood serum of the nesfatin-1 leads to remodeling of a myocardium of LV in the form of reduction of ability of a myocardium to reduction and increase of chambers and the LV sizes and can play a role in pathogenesis AH in patients with obesity.